UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 231

Sortiert nach

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

Journal of clinical oncology, 2012-09, Vol.30 (26), p.3264-3270

2012

Volltextzugriff (PDF)

Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma

International journal of cancer, 2014-11, Vol.135 (9), p.2199-2205

2014

Volltextzugriff (PDF)

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

PloS one, 2017-06, Vol.12 (6), p.e0178593-e0178593

2017

Volltextzugriff (PDF)

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.393-400

2016

Volltextzugriff (PDF)

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

Oncoimmunology, 2018-01, Vol.7 (8), p.e1461305-e1461305

2018

Volltextzugriff (PDF)

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma

Cancers, 2021-12, Vol.13 (24), p.6265

2021

Volltextzugriff (PDF)

Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease

Frontiers in oncology, 2023-01, Vol.12, p.1106597-1106597

2023

Volltextzugriff (PDF)

Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

Journal of clinical oncology, 2006-11, Vol.24 (33), p.5271-5276

2006

Volltextzugriff (PDF)

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Oncoimmunology, 2017-11, Vol.6 (11), p.e1358331

2017

Volltextzugriff (PDF)

Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine

Vaccines (Basel), 2024-06, Vol.12 (6), p.587

2024

Volltextzugriff (PDF)

Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma

Journal of clinical oncology, 2009-03, Vol.27 (7), p.1041-1046

2009

Volltextzugriff (PDF)

Ifosfamide, carboplatin, and etoposide for neuroblastoma

Cancer, 2013-02, Vol.119 (3), p.665-671

2013

Volltextzugriff (PDF)

Reduced Toxicity With Intensity Modulated Radiation Therapy (IMRT) for Desmoplastic Small Round Cell Tumor (DSRCT): An Update on the Whole Abdominopelvic Radiation Therapy (WAP-RT) Experience

International journal of radiation oncology, biology, physics, 2013, Vol.85 (1), p.e67-e72

2013

Volltextzugriff (PDF)

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

Journal of hematology and oncology, 2022-11, Vol.15 (1), p.1-12, Article 165

2022

Volltextzugriff (PDF)

Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma

Journal of pediatric hematology/oncology, 2017-10, Vol.39 (7), p.547-554

2017

Volltextzugriff (PDF)

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression

Journal of clinical oncology, 2021-01, Vol.39 (3), p.215-226

2021

Volltextzugriff (PDF)

Chemoimmunotherapy for high-risk neuroblastoma

The lancet oncology, 2017-07, Vol.18 (7), p.845-846

Kushner, Brian H

2017

Volltextzugriff (PDF)

FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

Journal of clinical oncology, 2006-06, Vol.24 (18), p.2885-2890

2006

Volltextzugriff (PDF)

Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma

Journal of clinical oncology, 2004-12, Vol.22 (24), p.4888-4892

2004

Volltextzugriff (PDF)

Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities

International journal of radiation oncology, biology, physics, 2018-12, Vol.102 (5), p.1457-1464

2018

Volltextzugriff (PDF)

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

The Journal of nuclear medicine (1978), 2016-02, Vol.57 (2), p.231-237

2016

Volltextzugriff (PDF)

Long-term complications in survivors of advanced stage neuroblastoma

Pediatric Blood & Cancer, 2005-09, Vol.45 (3), p.324-332

2005

Volltextzugriff (PDF)

Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults

Journal of clinical oncology, 2003-09, Vol.21 (18), p.3423-3430

2003

Volltextzugriff (PDF)

Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies

The Journal of nuclear medicine (1978), 2004-07, Vol.45 (7), p.1172-1188

Kushner, Brian H

2004

Volltextzugriff (PDF)

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

Clinical cancer research, 2014-03, Vol.20 (5), p.1375-1382

2014

Volltextzugriff (PDF)

1 – 25 von 231

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(208)
Mit Volltextzugriff
(216)

Publikationsform

Sprache

Englisch
(230)
Japanisch
(32)

Erscheinungsjahr

n.n

Thema

Humans
(154)
Science & Technology
(144)
Life Sciences & Biomedicine
(141)
Oncology
(113)
Male
(98)
Female
(97)
Child
(88)
Child, Preschool
(81)
Biological And Medical Sciences
(71)
Medical Sciences
(68)
Adolescent
(67)
Neuroblastoma
(67)
Infant
(65)
Pediatrics
(50)
Adult
(47)
Neuroblastoma - Drug Therapy
(47)
Neuroblastoma - Pathology
(44)
Neuroblastoma - Therapy
(41)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(37)
Tumors
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

Key role for myeloid cells: Phase II results of anti‐GD2 antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma

A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors

Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma

Adoptive immunotherapy with haploidentical natural killer cells and Anti-GD2 monoclonal antibody m3F8 for resistant neuroblastoma: Results of a phase I study

Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma

Skeletal muscle metastases in neuroblastoma share common progenitors with primary tumor and biologically resemble stage MS disease

Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Long Prime–Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer Vaccine

Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma

Ifosfamide, carboplatin, and etoposide for neuroblastoma

Reduced Toxicity With Intensity Modulated Radiation Therapy (IMRT) for Desmoplastic Small Round Cell Tumor (DSRCT): An Update on the Whole Abdominopelvic Radiation Therapy (WAP-RT) Experience

Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies

Long-term Pulmonary Outcomes in Pediatric Survivors of High-risk Neuroblastoma

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression

Chemoimmunotherapy for high-risk neuroblastoma

FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor

Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma

Short Hypofractionated Radiation Therapy in Palliation of Pediatric Malignancies: Outcomes and Toxicities

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study

Long-term complications in survivors of advanced stage neuroblastoma

Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young Adults

Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies

Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

Suchergebnisse filtern